-
Mashup Score: 1Promising results with glucocorticoids, tocilizumab for COVID-19-associated cytokine storm syndrome - 4 year(s) ago
Treatment with high-dose methylprednisolone, followed by the interleukin-6 inhibitor tocilizumab if needed, may improve outcomes for patients with COVID-19 and cytokine storm syndrome, suggest findings from the CHIC study published in the Annals of the Rheumatic Diseases.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1Further evidence for increased COVID-19 susceptibility in patients with rheumatic diseases - 4 year(s) ago
Retrospectively collected data suggest that patients with autoimmune rheumatic diseases from the Hubei province in China had a greater susceptibility to COVID-19 infection than their family members living in the same household during the outbreak.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Patients with autoimmune #rheumatic diseases are at increased risk for #COVID19 infection and should take “all necessary precautions to protect themselves,” say Lingli Dong (@HuazhongUST) & team in @TheLancetRheum #RheumCovid https://t.co/IsZf9opnPV
-
-
Mashup Score: 1IL-6 inhibitors show potential for COVID-19 - 4 year(s) ago
Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: IL-6 inhibitors #tocilizumab and #sarilumab warrant further investigation as add-on treatments for #COVID19, suggest the results of two studies published in @ARD_BMJ @SRAnesthesiaICU @AbbateAntonio @giovannilandoni #RheumCovid https://t.co/YjeAr2mW4V
-
-
Mashup Score: 1IL-6 inhibitors show potential for COVID-19 - 4 year(s) ago
Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: IL-6 inhibitors #tocilizumab and #sarilumab warrant further investigation as add-on treatments for #COVID19, suggest the results of two studies published in @ARD_BMJ @SRAnesthesiaICU @AbbateAntonio @giovannilandoni #RheumCovid https://t.co/YjeAr2mW4V
-
-
Mashup Score: 1
A large UK study using the OpenSAFELY analytics platform has identified autoinflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus as possible risk factors for COVID-19-related death.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News in brief: #RheumatoidArthritis & #lupus identified as possible risk factors for #COVID19 mortality in a study using the @OpenSafely platform published in @nature #RheumCovid @bengoldacre https://t.co/AloauQu5Ro
-
-
Mashup Score: 2
Findings from two studies suggest that patients with systemic lupus erythematosus across multiple countries have experienced issues with accessing hydroxychloroquine during the COVID-19 pandemic.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Patients with #lupus and their healthcare providers have experienced issues with #hydroxychloroquine access during the #COVID19 pandemic, suggest two studies published in @ARD_BMJ @pekor002 #RheumCovid https://t.co/nLSewXBp0b
-
-
Mashup Score: 0Colchicine shows potential for COVID-19 - 4 year(s) ago
Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: GRECCO-19 trial results reported by Spyridon Deftereos (@uoaofficial), @dvrachatis and co-authors in @JAMANetworkOpen suggest #colchicine warrants further investigation for the treatment of #COVID19 #RheumCovid https://t.co/grro0ksQzO
-
-
Mashup Score: 1
The American College of Rheumatology has issued a position statement supporting the use of telemedicine during and after the COVID-19 pandemic.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News in brief: @ACRheum issues position statement supporting the use of #telemedicine during and after the #COVID19 pandemic #RheumCovid https://t.co/2P5pv7GEel
-
-
Mashup Score: 0COVID-19: Support for further investigation of tocilizumab - 4 year(s) ago
Add-on treatment with the IL-6 inhibitor tocilizumab may improve outcomes for patients with severe COVID-19, suggest findings from two retrospective cohort studies.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Findings from two studies published in @EClinicalMed and @TheLancetRheum support further investigation of add-on #tocilizumab as a treatment option for #COVID19 #RheumCovid #coronavirus @tariqkewan @CovutMD https://t.co/nMk1mywZH9
-
-
Mashup Score: 0
Click through for further details on this announcement
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
Regulatory update: @US_FDA revokes its Emergency Use Authorization permitting chloroquine and #hydroxychloroquine treatment for certain hospitalized #COVID19 patients outside of clinical trial settings #RheumCovid https://t.co/1Vhr6JetY8
-
News: Findings from the CHIC study published in @ARD_BMJ by @sofiaramiro82 (@Zuyderland) & team suggest #glucocorticoids plus #tocilizumab may be a promising option for #COVID19-associated cytokine storm syndrome #RheumCovid https://t.co/7Vut417ZHg